Inflammation: A pivotal link between autoimmune diseases and atherosclerosis
Inflammation: A pivotal link between autoimmune diseases and atherosclerosis
复制标题
DOI：
10.1016/j.autrev.2005.12.006
复制
发表时间：
2006-05-01
影响因子：
13.6
通讯作者：
Abou-Raya, Suzan
中科院分区：
文献类型：
--
作者：
Abou-Raya, Anna;Abou-Raya, Suzan
早发冠心病已成为系统性自身免疫性疾病发病和死亡的主要原因。近年来的流行病学和发病机制研究表明，类风湿性关节炎（RA）和系统性红斑狼疮（SLE）等典型自身免疫性疾病的发病机制与动脉粥样硬化的发病机制有许多共同点。支持自身免疫和动脉粥样硬化之间联系的一些最显著的数据来自于对自身免疫性疾病（RA和SLE）患者的流行病学研究。许多流行病学观察表明，全身炎症与自身免疫性疾病（如RA和SLE）的心血管事件有关。炎症越来越多地被认为是动脉粥样硬化发病机制的核心，也是血管疾病的重要危险因素。全身炎症可被认为是加速动脉粥样硬化过程。在一般人群中，可溶性炎症介质（如C反应蛋白（CRP））的全身水平与心血管风险相关。CRP，或更具体地说，高敏感性-hsCRP，是全身炎症的标志物，已被确定为心血管风险的有效生物标志物。此外，他汀类药物的免疫调节和抗炎作用可能会影响其在慢性炎症性自身免疫性疾病中的效用。因此，用这样的试剂有效控制或抑制炎症应该包括在自身免疫性疾病的治疗设备中，目的是保护免受心血管疾病。(c)2006 Elsevier B. V.保留所有权利。
Premature coronary heart disease has emerged as a major cause of morbidity and mortality in systemic autoimmune diseases. Recent epidemiologic and pathogenesis studies have suggested a great deal in common between the pathogenesis of prototypic autoimmune disease such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and that of atherosclerosis. Some of the most remarkable data in support of a link between autoimmunity and atherosclerosis comes from epidemiological studies of patients with autoimmune disorders (RA and SLE). Many epidemiologic observations have linked systemic inflammation with the cardiovascular events in autoimmune disease such as RA and SLE. Inflammation is increasingly being considered central to the pathogenesis of atherosclerosis and an important risk factor for vascular disease. Systemic inflammation may be regarded as accelerating the atherosclerotic process. Systemic levels of soluble inflammatory mediators such as C-reactive protein (CRP) have been associated with cardiovascular risk in the general population. CRP, or more specifically high sensitivity-hsCRP, is a marker of systemic inflammation that has been identified as a valid biomarker of cardiovascular risk. Furthermore, the immunomodulatory and anti-inflammatory actions of statins may affect their utility in the context of chronic inflammatory autoimmune disease. Thus, effective control or dampening of inflammation, with such agents, should be included in the therapeutic armamentarium of autoimmune diseases with the aim of protecting against cardiovascular disease. (c) 2006 Elsevier B.V. All rights reserved.